News Room

Shanghai FTZ Fund invests in Ark Biosciences, an innovative R&D enterprise of antiviral drugs

2020-08-05

Recently, Shanghai FTZ Fund has invested in ARK Biosciences (ARKbio), an innovative R&D enterprise of antiviral drugs. ARKbio is committed to the R&D of innovative antiviral drugs and pediatric drugs. In 2019, the company successfully completed a global phase II clinical study (VICTOR). This study confirmed for the first time in history that an antiviral drug has therapeutic efficacy for RSV infection in hospitalized infants and can bring clinical benefits to the children.